Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
News|Articles|November 11, 2026
Breast Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026
Author(s)OncLive Staff
Fact checked by: Ashling Wahner
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Advertisement
Advertisement
October brought an FDA approval for patients with HER2-positive breast cancer, a wave of phase 3 data from the 2026 ESMO Congress (ESMO 2026), international regulatory updates, and expert perspectives on oral selective estrogen receptor degraders, survivorship, and brain metastases.
Related to this article
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Advertisement
Advertisement